HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: iovs.08-1751v1 49/7/2799    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (3) Citing Articles via Google Scholar Google Scholar Articles by Boutrid, H. Articles by Cebulla, C. M. Search for Related Content PubMed PubMed Citation Articles by Boutrid, H. Articles by Cebulla, C. M.

Targeting Hypoxia, a Novel Treatment for Advanced Retinoblastoma

¹From the Bascom Palmer Eye Institute, Department of Ophthalmology, University of Miami Miller School of Medicine, Miami, Florida; and the ²Department of Cell Biology and Anatomy, University of Miami Miller School of Medicine and Sylvester Comprehensive Cancer Center, Miami, Florida.

PURPOSE. The purpose of this study was to evaluate the presence and extent of hypoxia in murine retinoblastoma tumors and the feasibility of targeting hypoxic cells as a novel therapeutic strategy.

METHODS. Hypoxic and vascular areas in LH_BETAT_AG mouse retinal tumors were measured using immunohistochemistry. The glycolytic inhibitor 2-deoxy-D-glucose (2-DG) was used to test the efficacy of targeting hypoxic cells in retinoblastoma. Sixteen-week-old LH_BETAT_AG mice received injections of saline, carboplatin (31.25 µg/20 µL), 2-DG (500 mg/kg), and carboplatin (31.25 µg/20 µL) + 2-DG (500 mg/kg). Carboplatin was administered through biweekly subconjunctival injections to right eyes only for 3 weeks. 2-DG was administered through intraperitoneal injection three times a week for 5 weeks. Saline was administered using both methods. Eyes were enucleated at 21 weeks of age and examined for residual tumor.

RESULTS. Hypoxic regions were observed in tumors larger than 3.28 mm². When 2-DG was combined with carboplatin, a marked decrease in tumor burden was observed that was significantly more pronounced than when either agent was given alone. The hypoxic tumor cell population as measured by pimonidazole was markedly reduced by carboplatin + 2-DG (P < 0.01) and by 2-DG alone (P < 0.01), but not by carboplatin alone, indicating that 2-DG effectively killed hypoxic retinoblastoma cells in vivo.

CONCLUSIONS. Treatment with glycolytic inhibitors as adjuvants to chemotherapy has the potential to increase the efficacy of chemotherapy in advanced retinoblastoma. This approach may have benefits for children with this disease and should be further investigated.

This article has been cited by other articles:

				H. Boutrid, Y. Pina, C. M. Cebulla, W. J. Feuer, T. J. Lampidis, M.-E. Jockovich, and T. G. Murray Increased Hypoxia following Vessel Targeting in a Murine Model of Retinoblastoma Invest. Ophthalmol. Vis. Sci., December 1, 2009; 50(12): 5537 - 5543. [Abstract] [Full Text] [PDF]